This pilot study will gather data to help better understand the effects of two HIV medications (tenofovir and zidovudine) on infants’ health. Study researchers will examine if tenofovir exposure during an HIV-positive mother’s pregnancy affects the bones and kidneys of her uninfected infant, and if those effects are different from infants who were exposed to zidovudine. Infants will be assessed for any signs of mitochondrial toxicity and whether there is a difference in toxicity between tenofovir and zidovudine exposed infants.
Currently, use of tenofovir-based antiretroviral therapy regimens in pregnant women living with HIV to prevent transmission to the baby is not routinely recommended because of a lack of safety and efficacy information. However, more women are taking tenofovir-based regimens during pregnancy for different reasons (resistance, treatment of other infections, preference, etc.). Therefore, it is important to understand the effects tenofovir exposure may have on infants’ health.
Eligible participants will be asked some general health questions about the infant’s medical history and also the mother’s medical and pregnancy history. This information would include the mother’s age and race, as well as medications she was taking and blood work results.The study visits will occur when the infant is 1-month, 6-months and 18-months of age, and at the same time as regular clinic visits. At these visits, the following tests will be done: